Journal of the National Cancer Institute Advance Access originally published online on August 8, 2007
JNCI Journal of the National Cancer Institute 2007 99(16):1232-1239; doi:10.1093/jnci/djm086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ARTICLES |
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Affiliations of authors: Genentech, Inc, South San Francisco, CA (FAS, JRS, SNH, HPG, JN, EH, JW); Indiana Cancer Pavilion, Indianapolis, IN (KM); Department of Medicine, University of California at Los Angeles, Los Angeles, CA (FK); University of California at San Francisco Cancer Center, San Francisco, CA (EB); Duke University Medical Center, Durham, NC (HH)
Correspondence to: Frank A. Scappaticci, MD, PhD, Genentech, Inc, BioOncology, 455 East Grand Ave, South San Francisco, CA 94080 (e-mail: anthon{at}gene.com).
Background: Although combination treatment with bevacizumab (humanized monoclonal antibody against vascular endothelial growth factor) and chemotherapy improves survival of patients with various metastatic carcinomas, an increased risk of arterial thromboembolic events has been observed in some trials. We characterized this risk by performing post hoc analyses of randomized controlled trials that evaluated combination treatment with bevacizumab and chemotherapy versus chemotherapy alone. Low-dose aspirin was permitted in these trials, and its safety was also analyzed.
Methods: Data were pooled from five randomized controlled trials that included a total of 1745 patients with metastatic colorectal, breast, or non–small-cell lung carcinoma. The risk of an arterial or venous thromboembolic event was assessed by simple incidence rates, rates per 100 person-years, and/or hazard ratios (HRs). The association between patient characteristics and risk of an arterial thromboembolic event was investigated primarily by Cox proportional hazards regression. The relationship between low-dose aspirin and bleeding was explored by incidence rates and rates per 100 person-years.
Results: Combined treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with increased risk for an arterial thromboembolic event (HR = 2.0, 95% confidence interval [CI] = 1.05 to 3.75; P = .031) but not for a venous thromboembolic event (HR = 0.89, 95% CI = 0.66 to 1.20; P = .44). The absolute rate of developing an arterial thromboembolism was 5.5 events per 100 person-years for those receiving combination therapy and 3.1 events per 100 person-years for those receiving chemotherapy alone (ratio = 1.8, 95% CI = 0.94 to 3.33; P = .076). Development of an arterial thromboembolic event was associated with a prior arterial thromboembolic event (P<.001) or age of 65 years or older (P = .01). Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events in both treatment groups, from 3.6% to 4.7% for bevacizumab-treated patients and from 1.7% to 2.2% for control subjects.
Conclusions: Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thromboembolism.
| CONTEXT AND CAVEATS Prior knowledge An increased risk of arterial thromboembolic events had been observed in some clinical trials of combination treatment with bevacizumab (humanized monoclonal antibody against vascular endothelial growth factor) and chemotherapy in patients with various metastatic carcinomas. Study design Pooled analysis of five randomized controlled trials that included a total of 1745 patients with metastatic cancer Contribution Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with a modest increase in the risk of arterial thromboembolism but not venous thromboembolism. The absolute rate of developing an arterial thromboembolic event was 5.5 per 100 person-years for those in the bevacizumab group and 3.1 for those in the chemotherapy-alone group. Risk factors associated with an arterial thromboembolic event were history of an arterial thromboembolic event and age 65 years or older. Implications The risk factors for arterial thromboembolism should be considered when making treatment decisions for individual patients. Limitations Raw incidence rates may have overestimated the risk of an arterial thromboembolic event because of the delayed time to progression in the bevacizumab-treated group compared with the control group. Associations between risk of an arterial thromboembolic event and different tumor or histologic types, between risk and different chemotherapeutic agents combined with bevacizumab, and between risk and different disease settings (especially, metastatic versus adjuvant settings) could not be assessed.
|
Manuscript received October 25, 2006; revised June 12, 2007; accepted July 3, 2007.
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1213.
J Natl Cancer Inst 2007 99: 1213.
This article has been cited by other articles:
|
|
 |
|
  M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action J. Clin. Oncol., October 10, 2009; 27(29): 4919 - 4926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Khorana and G. C. Connolly Assessing Risk of Venous Thromboembolism in the Patient With Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4839 - 4847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Lyman and A. A. Khorana Cancer, Clots and Consensus: New Understanding of an Old Problem J. Clin. Oncol., October 10, 2009; 27(29): 4821 - 4826. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Khorana Cancer and thrombosis: implications of published guidelines for clinical practice Ann. Onc., October 1, 2009; 20(10): 1619 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kozloff, M. U. Yood, J. Berlin, P. J. Flynn, F. F. Kabbinavar, D. M. Purdie, M. A. Ashby, W. Dong, M. M. Sugrue, A. Grothey, et al. Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study Oncologist, September 1, 2009; 14(9): 862 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T.H. Yeh and C. L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Artunay, E. Yuzbasioglu, R. Rasier, A. Sengul, and H. Bahcecioglu Acute retinal arterial occlusion after intravenous administration of bevacizumab BMJ Case Reports, May 17, 2009; 2009(may17_1): bcr0120091478 - bcr0120091478. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Gressett and S. R Shah Intricacies of Bevacizumab-Induced Toxicities and Their Management Ann. Pharmacother., March 1, 2009; 43(3): 490 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Thomas, J. S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, A. Kaseb, K. Glover, M. Davila, and J. Abbruzzese Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma J. Clin. Oncol., February 20, 2009; 27(6): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bollee, N. Patey, G. Cazajous, C. Robert, J.-M. Goujon, F. Fakhouri, P. Bruneval, L.-H. Noel, and B. Knebelmann Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib Nephrol. Dial. Transplant., February 1, 2009; 24(2): 682 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials J. Clin. Oncol., January 10, 2009; 27(2): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Khorana and G. H. Lyman Incidence and Prevention of Cancer-associated Thrombosis ASCO Educational Book, January 1, 2009; 2009(1): 321 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L J Singerman, H Masonson, M Patel, A P Adamis, R Buggage, E Cunningham, M Goldbaum, B Katz, and D Guyer Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol, December 1, 2008; 92(12): 1606 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis JAMA, November 19, 2008; 300(19): 2277 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Garfield and A. Hercbergs Fewer Dollars, More Sense J. Clin. Oncol., November 10, 2008; 26(32): 5304 - 5305. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pereg and M. Lishner Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur. Heart J., October 1, 2008; 29(19): 2325 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Nachman and S. Rafii Platelets, Petechiae, and Preservation of the Vascular Wall N. Engl. J. Med., September 18, 2008; 359(12): 1261 - 1270. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Levey, R. S. Bajwa, M. M. Picken, J. I. Clark, K. Barton, and D. J. Leehey Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation NDT Plus, June 1, 2008; 1(3): 154 - 156. [Full Text] [PDF]
|
|
|
|
|
|
J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann. Onc., April 1, 2008; 19(4): 734 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lichtman Pharmacology of Antineoplastic Agents for Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman The Risk of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248. [Abstract] [Full Text] [PDF]
|
|